CRNX Crinetics Pharmaceuticals, Inc. - Common Stock
$84.77
价格 · 八月 19, 2026
截至...的财报数据 八月 3, 2026
52周区间
$29–$85
100% of range
分析师评级
HOLD
21 analysts
目标价
$86
+1% upside
P/E (TTM)
-17.1
ROE
-43.0%
净利润率
-6046.2%
关于 Crinetics Pharmaceuticals, Inc. - Common Stock 公司概况（来自维基百科）
Crinetics Pharmaceuticals is a global pharmaceutical company known for developing drugs for the treatment of endocrine-related diseases. It was founded by Scott Struthers, Frank Zhu, Ana Kusnetzow, and Stephen F. Betz in 2008 and is headquartered in San Diego, California. It went public on NASDAQ in 2018.
阅读更多
Crinetics Pharmaceuticals is a global pharmaceutical company known for developing drugs for the treatment of endocrine-related diseases. It was founded by Scott Struthers, Frank Zhu, Ana Kusnetzow, and Stephen F. Betz in 2008 and is headquartered in San Diego, California. It went public on NASDAQ in 2018.
In July 2026, Vertex Pharmaceuticals agreed to acquire the company for $10 billion.
History
Struthers, Zhu, Kusnetzow, and Betz founded Crinetics in 2008 after previously working together on a small molecule drug for the treatment of endometriosis at Neurocrine Biosciences.
Crinetics expanded into a larger laboratory in 2010. After receiving NIH grant funding, Crinetics moved into its second laboratory.
In 2011, Crinetics Pharmaceuticals competed for the Michelson Prize, a competition sponsored by the Found Animals Foundation to develop a low-cost, non-surgical method for sterilizing dogs and cats, which would later lead to the licensing of a molecule for the treatment of acromegaly in large breed dogs.
Crinetics first synthesized its lead drug candidate to treat acromegaly. The drug was named paltusotine, in 2016. Crinetics Pharmaceuticals went public with an IPO in 2018. It conducted Phase II trials for paltusotine from 2019 to 2020. It conducted Phase III trials for paltusotine from 2021 to 2024. After the drug succeeded in a second Phase III study, the FDA accepted the company's new drug application for paltusotine and the company announced it was planning for a 2025 launch for the drug. The FDA set a Prescription Drug User Fee Act for the drug on September 25, 2025.
In 2021, Crinetics, together with 5AM Ventures and Frazier Healthcare Partners, formed an independently operated new company, Radionetics Oncology, aimed to develop a deep pipeline of novel, targeted, nonpeptide radiopharmaceuticals for the treatment of a broad range of oncology indications.
Crinetics partnered with the veterinary medicine company Loyal to develop a pill to extend the lifespans of large dogs in 2023.
In 2024, Scott Struthers received the Ernst & Young Entrepreneur of the Year Award for his work with Crinetics. In 2024, Crinetics was reported to have patent activity in rare diseases, health technology, and addiction therapies.
In 2024, Radionetics formed a strategic relationship with Eli Lilly and Company to take forward Radionetics’ proprietary GPCR targeting small molecule radiopharmaceuticals. Under the terms of the agreement, Radionetics received a $140 million upfront cash payment. As part of the strategic agreement, Lilly obtained the exclusive right to acquire Radionetics upon conclusion of an exercise period for $1 billion.
Crinetics also established its first office outside the United States in Zug, Switzerland in 2024.
In 2025, Crinetics Pharmaceuticals plans to file an Investigational New Drug for an oral thyroid stimulating hormone receptor antagonist and its nonpeptide drug conjugate (CRN09682). A total of four development candidates are currently in IND-enabling studies, including a PTH antagonist (Hyperparathyrodism), non-peptide drug conjugate (NETs and SST2-expressing solid tumors), TSH antagonist (Graves’ disease & TED) and SST3 agonist (ADPKD).
In July 2026, Vertex Pharmaceuticals agreed to acquire Crinetics for $10 billion.
Treatments
Crinetics’ pipeline focuses on synthesizing novel molecules for rare endocrine diseases. It is most known for developing paltusotine, a drug designed to treat the hormonal disorder acromegaly. Paltusotine works by helping moderate elevated IGF-1 levels, which is the main symptom of acromegaly. Paltusotine has also been tested as a treatment for carcinoid syndrome.
Crinetics has also developed oral treatments for neuroendocrine tumors, hyperinsulism, and Cushing's disease. The company's drug for treating Cushing's disease, Atumeltnant (also known as CRN049894), works by reducing levels of ACTH.
The company's pipeline also includes an oral parathyroid hormone inhibitor program for hyperparathyroidism and treatments for thyroid eye disease, Graves' disease, and obesity. Additionally, Crinetics nonpeptide drug conjugates (NDCs) include CRN09682, which is a somatostatin receptor 2 (SST2) targeted drug. NDCs are a new technology developed in-house by Crinetics.
== References ==
来源：维基百科 (英语), CC BY-SA 4.0 · 在维基百科上查看 ↗
CRNX 股票快照 价格、市值、P/E、EPS、ROE、负债/权益、52周范围
价格
$84.77
市值
$8.10B
P/E (TTM)
-17.1
每股收益 (TTM)
$-4.95
营收 (TTM)
$8M
股息收益率
—
ROE
-43.0%
负债/权益
—
52周区间
$29 – $85
CRNX 股价图表 包含技术指标的日 OHLCV — 平移、缩放和自定义您的视图
Configure
10年表现 收入、净利润、利润率和每股收益趋势
营收与净利润
$8M
2016-12-31
→
2025-12-31
EPS
$-4.95
2020-12-31
→
2025-12-31
自由现金流
$-384M
2018-12-31
→
2025-12-31
利润率
-6046.2%
估值 P/E、P/S、P/B、EV/EBITDA 比率 — 该股票是昂贵还是便宜？
指标
5年趋势
CRNX
同行中位数
P/E (TTM)
-17.1
47.9
P/S (TTM) (市销率 (TTM))
1052.7
16.2
P/B (市净率)
8.2
9.3
Price / FCF (股价/自由现金流)
-21.1
—
盈利能力 毛利率、营业利润率和净利率；股本回报率 (ROE)、资产回报率 (ROA)、投入资本回报率 (ROIC)
指标
5年趋势
CRNX
同行中位数
Operating Margin (营业利润率)
-6714.8%
—
Net Profit Margin (净利润率)
-6046.2%
5.1%
ROA
-36.3%
0.81%
ROE
-43.0%
-15.3%
ROIC
-52.1%
—
财务健康 债务、流动性、偿付能力 — 资产负债表强度
指标
5年趋势
CRNX
同行中位数
Current Ratio (流动比率)
12.3
2.7
Quick Ratio (速动比率)
12.1
—
成长 营收、每股收益 (EPS) 和净利润增长：同比、3年复合年增长率 (CAGR)、5年复合年增长率 (CAGR)
指标
5年趋势
CRNX
同行中位数
Revenue YoY (营收同比增长)
640.7%
—
Revenue CAGR 3Y (营收3年复合年增长率)
17.6%
—
Revenue CAGR 5Y (营收5年复合年增长率)
155.3%
—
资本效率 资产周转率、库存周转率、应收账款周转率
指标
5年趋势
CRNX
同行中位数
CRNX 分析师共识 看涨和看跌分析师观点、12个月价格目标、上涨空间
持有
21 位分析师
- 强烈买入 3 14.3%
- 买入 4 19.0%
- 持有 14 66.7%
- 卖出 0 0.0%
- 强烈卖出 0 0.0%
12个月价格目标
10 位分析师 · 2026-08-13
中位数
$85.00
平均值
$85.50
← 低于所有目标
$84.77
最低
$85.00
最高
$90.00
中位数目标
$85.00
+0.3%
平均目标
$85.50
+0.9%
收益历史 每股收益实际值 vs 预估值，惊喜%，达标率，下次财报日期
平均惊喜
-0.01%
| 期间 | EPS Actual | EPS 预期 | 惊喜 |
|---|---|---|---|
| 2026年6月30日 | $-1.14 | $-1.23 | 0.09% |
| 2026年3月31日 | $-1.23 | $-1.26 | 0.03% |
| 2025年12月31日 | $-1.29 | $-1.39 | 0.10% |
| 2025年9月30日 | $-1.38 | $-1.28 | -0.10% |
| 2025年6月30日 | $-1.23 | $-1.12 | -0.11% |
| 2025年3月31日 | $-1.04 | $-0.96 | -0.08% |
同行比较（GICS 子行业） 关键指标与行业同行对比
| 股票代码 | 市值 | P/E | 营收同比增长 | 净利润率 | ROE | 毛利率 |
|---|---|---|---|---|---|---|
| CRNX | $4.45B | -9.4 | 640.7% | -6046.2% | -43.0% | — |
| CORT | $3.69B | 42.4 | 12.8% | 13.1% | 15.5% | — |
| ELAN | $11.25B | -48.1 | 6.2% | -4.9% | -3.5% | 55.0% |
| AXSM | $9.29B | -49.6 | 65.5% | -28.7% | -227.0% | — |
| LQDA | $3.01B | -43.1 | 1031.2% | -43.5% | -230.0% | — |
| BLTE | — | — | — | — | — | — |
| DFTX | $1.32B | -6.5 | 212.0% | — | -71.0% | — |
| AMRX | — | 57.3 | 8.1% | 2.4% | -80.0% | 36.9% |
| LGND | $3.74B | 30.8 | 60.4% | 46.4% | 13.5% | — |
| LLY | — | 46.8 | 44.7% | 31.7% | 101.2% | — |
完整基本面 所有年度指标 — 损益表、资产负债表、现金流量表
损益表 17
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8M | $1M | $4M | $5M | $1M | $71.0K | $1M | $2M | $2M | |
| Cost of Revenue | $1M | $0 | $0 | · | · | · | · | · | · | |
| R&D Expense | $332M | $240M | $169M | $130M | $84M | $57M | $42M | $24M | $9M | |
| SG&A Expense | $191M | $100M | $58M | $42M | $25M | $18M | $14M | $7M | $2M | |
| Operating Expenses | $524M | $340M | $227M | $173M | $109M | $75M | $55M | $31M | $11M | |
| Operating Income | $-517M | $-339M | $-223M | $-168M | $-108M | $-75M | $-54M | $-29M | $-9M | |
| Interest Expense | · | · | · | · | · | · | · | · | $8.0K | |
| Interest Income | $52M | $41M | $13M | $4M | $157.0K | $991.0K | $3M | $2M | $26.0K | |
| Other Non-op | $-357.0K | $-519.0K | $-159.0K | $5M | $61.0K | $1M | $3M | $2M | $-30.0K | |
| Pretax Income | $-465M | $-298M | $-209M | $-164M | $-108M | $-74M | $-50M | $-27M | $-9M | |
| Income Tax | $180.0K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-465M | $-298M | $-215M | $-164M | $-108M | $-74M | $-50M | $-27M | $-9M | |
| EPS (Basic) | $-4.95 | $-3.69 | $-3.69 | $-3.15 | $-2.80 | $-2.42 | · | · | · | |
| EPS (Diluted) | $-4.95 | $-3.69 | $-3.69 | $-3.15 | $-2.80 | $-2.42 | · | · | · | |
| Shares (Basic) | 94,057,000 | 80,783,000 | 58,071,000 | 51,982,000 | 38,436,000 | 30,448,000 | · | · | · | |
| Shares (Diluted) | 94,057,000 | 80,783,000 | 58,071,000 | 51,982,000 | 38,436,000 | 30,448,000 | · | · | · | |
| EBITDA | $-513M | $-339M | $-223M | $-168M | $-108M | $-75M | $-54M | $-29M | · |
资产负债表 24
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $102M | $265M | $55M | $33M | $201M | $93M | $40M | $45M | $14M | |
| Short-term Investments | $926M | $1.09B | $504M | $302M | $133M | $78M | $78M | $119M | · | |
| Receivables | $592.0K | $0 | · | · | · | · | · | · | · | |
| Inventory | $2M | $0 | · | · | · | · | · | · | · | |
| Prepaid Expense | $18M | $21M | $16M | $11M | $11M | $7M | $5M | $3M | $973.0K | |
| Other Current Assets | $3M | $2M | $448.0K | $2M | $912.0K | $1M | $668.0K | $876.0K | $239.0K | |
| Current Assets | $1.05B | $1.38B | $574M | $345M | $345M | $177M | $123M | $167M | $15M | |
| PP&E (Net) | $14M | $12M | $11M | $4M | $3M | $3M | $4M | $4M | $400.0K | |
| PP&E (Gross) | $22M | $20M | $16M | $8M | $6M | $6M | $6M | $5M | $704.0K | |
| Accum. Depreciation | $8M | $8M | $5M | $4M | $3M | $3M | $2M | $741.0K | $304.0K | |
| Other Non-current Assets | · | $3M | $2M | $37.0K | $0 | $40.0K | $82.0K | · | $33.0K | |
| Total Assets | $1.13B | $1.43B | $635M | $352M | $351M | $183M | $130M | $171M | $16M | |
| Accounts Payable | $23M | $6M | $7M | $7M | $3M | $6M | $5M | $5M | $403.0K | |
| Accrued Liabilities | · | · | · | · | · | · | · | $4M | $179.0K | |
| Current Liabilities | $85M | $60M | $44M | $28M | $16M | $10M | $8M | $8M | $897.0K | |
| Capital Leases | $42M | $45M | $48M | $2M | $3M | $4M | $5M | · | · | |
| Other Non-current Liabilities | $3M | $829.0K | $0 | · | · | · | · | · | · | |
| Total Liabilities | $134M | $110M | $96M | $36M | $19M | $15M | $13M | $11M | $920.0K | |
| Common Stock | · | · | $253.0K | $0 | · | · | · | $24.0K | $1.0K | |
| Retained Earnings | $-1.42B | $-952M | $-654M | $-439M | $-275M | $-168M | $-94M | $-43M | $-16M | |
| AOCI | $2M | $963.0K | $977.0K | $-4M | $-382.0K | $25.0K | $148.0K | $61.0K | · | |
| Stockholders' Equity | $992M | $1.32B | $539M | $316M | $332M | $169M | $117M | $160M | $-15M | |
| Liabilities + Equity | $1.13B | $1.43B | $635M | $352M | $351M | $183M | $130M | $171M | $16M | |
| Shares Outstanding | 95,575,000 | 92,926,000 | 68,175,000 | 53,877,000 | 47,597,000 | 33,001,000 | 24,263,000 | 24,061 | 1,549,575 |
现金流 13
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $4M | $3M | $1M | $983.0K | $922.0K | $948.0K | $887.0K | $471.0K | $128.0K | |
| Stock-based Comp | $91M | $69M | $41M | $28M | $17M | $10M | $6M | $2M | $271.0K | |
| Deferred Tax | $0 | $0 | $0 | · | · | · | · | · | · | |
| Other Non-cash | $-8M | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-378M | $-230M | $-169M | $-115M | $-89M | $-62M | $-46M | $-19M | $-9M | |
| CapEx | $6M | $4M | $5M | $2M | $436.0K | $186.0K | $492.0K | $1M | $304.0K | |
| Investing Cash Flow | $174M | $-575M | $-200M | $-174M | $-56M | $217.0K | $42M | $-119M | $-304.0K | |
| Stock Issued | $0 | $985M | $370M | $117M | $250M | $114M | · | $106M | · | |
| Net Stock Activity | $0 | $970M | $369M | $117M | $250M | $114M | · | · | · | |
| Financing Cash Flow | $41M | $1.01B | $391M | $122M | $253M | $115M | $67.0K | $170M | $12M | |
| Net Change in Cash | · | $210M | $22M | $-167M | $108M | $53M | $-5M | $31M | $2M | |
| Taxes Paid | $89.0K | $0 | $0 | · | · | · | · | · | · | |
| Free Cash Flow | $-384M | $-230M | $-171M | $-117M | $-89M | $-62M | $-47M | $-21M | · |
盈利能力 7
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -6714.8% | -32613.5% | -5547.2% | -3544.1% | -9990.9% | -105567.6% | -4512.3% | -1182.5% | · | |
| Net Margin | -6046.2% | -28720.7% | -5345.9% | -3460.4% | -9985.2% | -103960.6% | -4226.5% | -1116.8% | · | |
| Pretax Margin | -6043.9% | -28720.7% | -5345.9% | -3460.4% | -9985.2% | -103960.6% | -4226.5% | -1116.8% | · | |
| EBITDA Margin | -6664.1% | -32613.5% | -5547.2% | -3544.1% | -9990.9% | -105567.6% | -4512.3% | -1182.5% | · | |
| ROA | -36.3% | -28.8% | -43.5% | -46.6% | -40.3% | -47.0% | -33.4% | -29.0% | · | |
| ROE | -43.0% | -27.7% | -39.5% | -49.1% | -41.0% | -41.4% | -40.9% | -16.6% | · | |
| ROIC | -52.1% | -25.6% | -41.3% | -53.1% | -32.5% | -44.4% | -46.0% | -17.9% | · |
流动性与偿付能力 2
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 12.3 | 23.0 | 13.1 | 12.5 | 21.6 | 16.9 | 14.8 | 21.0 | · | |
| Quick Ratio | 12.1 | 22.7 | 12.7 | 12.1 | 20.9 | 16.3 | 14.2 | 20.7 | · |
效率 3
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | |
| Inventory Turnover | 1.1 | · | · | · | · | · | · | · | · | |
| Receivables Turnover | 26.0 | · | · | · | · | · | · | · | · |
增长率 3
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 640.7% | -74.1% | -15.3% | 339.4% | 1418.3% | · | · | · | · | |
| Revenue CAGR 3Y | 17.6% | -1.2% | 283.8% | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 155.3% | · | · | · | · | · | · | · | · |
估值 (TTM) 10
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $8M | $1M | $4M | $5M | $1M | $71.0K | $1M | $2M | · | |
| Net Income TTM | $-465M | $-298M | $-215M | $-164M | $-108M | $-74M | $-50M | $-27M | · | |
| Market Cap | $4.45B | $4.75B | $2.43B | $986M | $1.35B | $466M | $608.8K | $722M | · | |
| P/E | -9.4 | -13.9 | -9.6 | -5.8 | -10.1 | -5.8 | · | · | · | |
| P/S | 578.1 | 4573.0 | 604.5 | 208.1 | 1254.4 | 6558.4 | 0.5 | 297.2 | · | |
| P/B | 4.5 | 3.6 | 4.5 | 3.1 | 4.1 | 2.8 | 0.0 | 4.5 | · | |
| P / Tangible Book | 4.5 | 3.6 | 4.5 | 3.1 | 4.1 | 2.8 | · | · | · | |
| P / Cash Flow | -11.8 | -21.0 | -14.6 | -8.6 | -15.3 | -7.5 | -0.0 | -37.1 | · | |
| P / FCF | -11.6 | -20.7 | -14.2 | -8.4 | -15.2 | -7.5 | -0.0 | -35.2 | · | |
| Earnings Yield | -10.6% | -7.2% | -10.4% | -17.2% | -9.9% | -17.2% | · | · | · |
损益表 15
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $25M | $11M | $6M | $143.0K | $1M | $361.0K | $0 | $0 | $399.0K | $640.0K | $0 | $346.0K | $988.0K | $3M | $709.0K | $458.0K | |
| Cost of Revenue | $154.0K | $200.0K | · | · | $0 | $0 | · | · | · | · | · | · | · | · | · | · | |
| R&D Expense | $100M | $100M | $85M | $90M | $80M | $76M | $67M | $62M | $58M | $53M | $46M | $44M | $41M | $38M | $37M | $32M | |
| SG&A Expense | $58M | $51M | $54M | $52M | $50M | $36M | $28M | $26M | $25M | $21M | $17M | $15M | $13M | $12M | $11M | $12M | |
| Operating Expenses | $158M | $151M | $140M | $143M | $130M | $112M | $95M | $88M | $83M | $74M | $63M | $59M | $54M | $51M | $48M | $44M | |
| Operating Income | $-132M | $-140M | $-134M | $-143M | $-129M | $-111M | $-95M | $-88M | $-83M | $-74M | $-63M | $-59M | $-53M | $-48M | $-48M | $-43M | |
| Interest Income | $12M | $13M | $11M | $13M | $13M | $15M | $14M | $11M | $9M | $7M | $7M | $3M | $2M | $2M | $2M | $2M | |
| Other Non-op | $-423.0K | $-131.0K | $-28M | $-49.0K | $20.0K | $-203.0K | $-16M | $-37.0K | $9M | $7M | $-7M | $3M | $2M | $2M | $3M | $2M | |
| Pretax Income | · | · | $-123M | $-130M | · | · | $-81M | $-77M | · | · | · | · | · | · | · | · | |
| Net Income | $-121M | $-128M | $-123M | $-130M | $-116M | $-97M | $-81M | $-77M | $-74M | $-67M | $-60M | $-57M | $-51M | $-46M | $-45M | $-42M | |
| EPS (Basic) | $-1.14 | $-1.23 | $-1.30 | $-1.38 | $-1.23 | $-1.04 | $-0.86 | $-0.96 | $-0.94 | $-0.93 | $-0.89 | $-1.01 | $-0.94 | $-0.85 | $-0.83 | $-0.78 | |
| EPS (Diluted) | $-1.14 | $-1.23 | $-1.30 | $-1.38 | $-1.23 | $-1.04 | $-0.86 | $-0.96 | $-0.94 | $-0.93 | $-0.89 | $-1.01 | $-0.94 | $-0.85 | $-0.83 | $-0.78 | |
| Shares (Basic) | 105,560,000 | 104,099,000 | -187,051,000 | 94,215,000 | 93,791,000 | 93,102,000 | -150,605,000 | 80,091,000 | 79,008,000 | 72,289,000 | -106,920,000 | 56,808,000 | 54,275,000 | 53,908,000 | -102,020,000 | 53,768,000 | |
| Shares (Diluted) | 105,560,000 | 104,099,000 | -187,051,000 | 94,215,000 | 93,791,000 | 93,102,000 | -150,605,000 | 80,091,000 | 79,008,000 | 72,289,000 | -106,920,000 | 56,808,000 | 54,275,000 | 53,908,000 | -102,020,000 | 53,768,000 | |
| EBITDA | $-132M | $-140M | · | $-143M | $-129M | $-111M | · | $-88M | $-83M | $-74M | · | $-59M | $-53M | $-48M | · | $-43M |
资产负债表 23
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $55M | $114M | $102M | $111M | $54M | $95M | $265M | $317M | $302M | $396M | $55M | $143M | $40M | $41M | $33M | $31M | |
| Short-term Investments | $1.15B | $1.18B | $926M | $981M | $1.14B | $1.18B | $1.09B | $545M | $561M | $505M | · | $412M | $225M | $255M | · | $337M | |
| Receivables | $12M | $6M | $592.0K | · | · | · | $0 | · | · | · | · | · | · | · | · | · | |
| Inventory | $3M | $3M | $2M | · | · | · | $0 | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $23M | $22M | $18M | $28M | $20M | $16M | $21M | $15M | $12M | $16M | · | $21M | $20M | $9M | · | $10M | |
| Other Current Assets | $5M | $6M | $3M | $5M | $4M | $3M | $2M | $1M | $2M | $4M | · | $4M | $3M | $3M | · | $2M | |
| Current Assets | $1.24B | $1.32B | $1.05B | $1.12B | $1.22B | $1.29B | $1.38B | $878M | $875M | $917M | · | $576M | $285M | $305M | · | $378M | |
| PP&E (Net) | $13M | $13M | $14M | $14M | $15M | $13M | $12M | $12M | $12M | $12M | · | $10M | $3M | $3M | · | $4M | |
| PP&E (Gross) | $23M | $23M | $22M | $21M | $24M | $21M | $20M | $19M | $18M | $17M | · | $15M | $8M | $8M | · | $7M | |
| Accum. Depreciation | $10M | $9M | $8M | $7M | $10M | $9M | $8M | $7M | $6M | $5M | · | $5M | $5M | $4M | · | $4M | |
| Other Non-current Assets | · | · | · | · | · | $14M | · | $3M | $2M | $2M | · | $2M | $2M | $2M | · | · | |
| Total Assets | $1.32B | $1.40B | $1.13B | $1.20B | $1.29B | $1.36B | $1.43B | $937M | $936M | $978M | · | $642M | $293M | $314M | · | $385M | |
| Accounts Payable | $13M | $13M | $23M | $6M | $11M | $10M | $6M | $5M | $9M | $11M | · | $6M | $5M | $6M | · | $6M | |
| Current Liabilities | $80M | $71M | $85M | $74M | $68M | $57M | $60M | $54M | $54M | $52M | · | $40M | $33M | $26M | · | $25M | |
| Capital Leases | $41M | $41M | $42M | $43M | $43M | $44M | $45M | $45M | $46M | $47M | · | $48M | $1M | $2M | · | $2M | |
| Other Non-current Liabilities | $6M | $5M | $3M | $3M | $2M | $2M | $829.0K | $511.0K | $202.0K | · | · | · | · | · | · | · | |
| Total Liabilities | $130M | $121M | $134M | $124M | $118M | $107M | $110M | $104M | $105M | $103M | · | $94M | $39M | $34M | · | $34M | |
| Common Stock | · | · | · | · | · | · | · | · | · | $881.0K | · | · | · | · | · | · | |
| Retained Earnings | $-1.67B | $-1.55B | $-1.42B | $-1.29B | $-1.16B | $-1.05B | $-952M | $-872M | $-795M | $-721M | · | $-594M | $-536M | $-485M | · | $-394M | |
| AOCI | $-3M | $-1M | $2M | $2M | $2M | $2M | $963.0K | $2M | $-190.0K | $150.0K | · | $-865.0K | $-2M | $-3M | · | $-5M | |
| Stockholders' Equity | $1.19B | $1.28B | $992M | $1.07B | $1.17B | $1.25B | $1.32B | $833M | $831M | $875M | $539M | $548M | $254M | $280M | $316M | $351M | |
| Liabilities + Equity | $1.32B | $1.40B | $1.13B | $1.20B | $1.29B | $1.36B | $1.43B | $937M | $936M | $978M | · | $642M | $293M | $314M | · | $385M | |
| Shares Outstanding | 105,808,000 | 105,314,000 | 95,575,000 | 94,548,000 | 94,126,000 | 93,525,000 | 92,926,000 | 80,841,000 | 79,322,000 | 78,539,000 | · | 66,708,000 | 54,682,000 | 53,990,000 | · | 53,796,000 |
现金流 10
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $1M | $994.0K | $1M | $959.0K | $925.0K | $788.0K | $770.0K | $753.0K | $474.0K | $262.0K | $273.0K | $280.0K | $283.0K | $280.0K | $248.0K | |
| Stock-based Comp | $25M | $30M | $22M | $23M | $26M | $20M | $19M | $18M | $19M | $13M | $12M | $11M | $10M | $8M | $8M | $7M | |
| Operating Cash Flow | $-94M | $-125M | $-93M | $-111M | $-86M | $-88M | $-67M | $-65M | $-48M | $-53M | $-41M | $-41M | $-46M | $-41M | $-35M | $-38M | |
| CapEx | $521.0K | $820.0K | $458.0K | $863.0K | $3M | $1M | $1M | $528.0K | $955.0K | $1M | $935.0K | $4M | $237.0K | $16.0K | $274.0K | $682.0K | |
| Investing Cash Flow | $26M | $-252M | $57M | $165M | $38M | $-86M | $-542M | $21M | $-54M | $309.0K | $-87M | $-193M | $31M | $49M | $37M | $7M | |
| Stock Issued | $0 | $381M | $0 | $0 | $0 | $0 | $544M | $63M | $10M | $383M | $29M | $329M | $11M | $0 | $0 | $-13.0K | |
| Net Stock Activity | · | $381M | · | · | · | $0 | · | · | · | $383M | · | · | · | · | · | · | |
| Financing Cash Flow | $9M | $390M | $26M | $3M | $7M | $4M | $556M | $59M | $8M | $394M | $40M | $338M | $13M | $484.0K | $115.0K | $1M | |
| Net Change in Cash | · | · | · | $57M | $-41M | $-170M | · | $15M | $-94M | $341M | · | $103M | $-2M | $9M | $2M | $-31M | |
| Free Cash Flow | · | $-126M | · | · | · | $-90M | · | · | · | $-54M | · | · | · | $-41M | · | · |
盈利能力 6
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -527.4% | -1307.8% | · | -99710.5% | -12523.0% | -30860.1% | · | · | -20747.6% | -11488.9% | · | -17045.4% | -5363.9% | -1790.9% | · | -9487.8% | |
| Net Margin | -481.1% | -1191.0% | · | -90972.7% | -11216.0% | -26807.2% | · | · | -18560.1% | -10457.8% | · | -16606.4% | -5159.8% | -1716.9% | · | -9153.9% | |
| Pretax Margin | · | · | · | -90972.7% | · | · | · | · | · | · | · | · | · | · | · | · | |
| EBITDA Margin | -527.4% | -1307.8% | · | -99710.5% | -12523.0% | -30860.1% | · | · | -20747.6% | -11488.9% | · | -17045.4% | -5363.9% | -1790.9% | · | -9487.8% | |
| ROA | -9.3% | -9.3% | · | -12.2% | -10.4% | -8.3% | · | -9.7% | -12.0% | -10.4% | · | -11.2% | -14.3% | -14.2% | · | -14.1% | |
| ROE | -10.2% | -10.1% | · | -13.7% | -11.6% | -9.1% | · | -11.1% | -13.7% | -11.6% | · | -12.8% | -15.9% | -15.8% | · | -15.4% |
流动性与偿付能力 2
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 15.6 | 18.6 | · | 15.1 | 17.8 | 22.5 | · | 16.4 | 16.1 | 17.7 | · | 14.2 | 8.7 | 11.6 | · | 15.4 | |
| Quick Ratio | 15.2 | 18.2 | · | 14.7 | 17.5 | 22.2 | · | 16.1 | 15.9 | 17.4 | · | 13.7 | 8.1 | 11.3 | · | 15.0 |
效率 3
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Inventory Turnover | 0.1 | 0.1 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Receivables Turnover | 4.2 | 3.8 | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
估值 (TTM) 10
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $37M | $12M | · | $2M | $2M | $1M | · | $1M | $2M | $5M | · | $4M | $5M | $7M | · | $4M | |
| Net Income TTM | $-494M | $-470M | · | $-419M | $-363M | $-315M | · | $-275M | $-249M | $-221M | · | $-196M | $-181M | $-165M | · | $-147M | |
| Market Cap | $3.96B | $3.83B | · | $3.94B | $2.71B | $3.14B | · | $4.13B | $3.55B | $3.68B | · | $1.98B | $985M | $867M | · | $1.06B | |
| P/E | -7.5 | -7.4 | · | -9.0 | -6.9 | -8.7 | · | -13.3 | -11.7 | -12.5 | · | -8.3 | -5.3 | -5.1 | · | -6.4 | |
| P/S | 106.9 | 311.8 | · | 2565.4 | 1511.5 | 2240.6 | · | 2982.7 | 1497.2 | 790.1 | · | 443.7 | 215.9 | 129.3 | · | 262.3 | |
| P/B | 3.3 | 3.0 | · | 3.7 | 2.3 | 2.5 | · | 5.0 | 4.3 | 4.2 | · | 3.6 | 3.9 | 3.1 | · | 3.0 | |
| P / Tangible Book | 3.3 | 3.0 | · | 3.7 | 2.3 | 2.5 | · | 5.0 | 4.3 | 4.2 | · | 3.6 | 3.9 | 3.1 | · | 3.0 | |
| P / Cash Flow | · | -30.7 | · | · | · | -35.5 | · | · | · | -69.6 | · | · | · | -21.3 | · | · | |
| P / FCF | · | -30.5 | · | · | · | -35.0 | · | · | · | -67.8 | · | · | · | -21.3 | · | · | |
| Earnings Yield | -13.3% | -13.4% | · | -11.1% | -14.5% | -11.5% | · | -7.5% | -8.5% | -8.0% | · | -12.0% | -18.8% | -19.7% | · | -15.5% |
财务报表 损益表、资产负债表、现金流量表 — 年度，近5年
损益表
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 收入 | $8M | $1M | $4M | $5M | $1M |
| 营业利润率 % | -6714.8% | -32613.5% | -5547.2% | -3544.1% | -9990.9% |
| 净收入 | $-465M | $-298M | $-215M | $-164M | $-108M |
| 稀释后每股收益 (EPS) | $-4.95 | $-3.69 | $-3.69 | $-3.15 | $-2.80 |
资产负债表
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 流动比率 | 12.3 | 23.0 | 13.1 | 12.5 | 21.6 |
| 速动比率 | 12.1 | 22.7 | 12.7 | 12.1 | 20.9 |
现金流
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 自由现金流 | $-384M | $-230M | $-171M | $-117M | $-89M |
最新新闻 提及该公司的近期头条新闻
- Vertex to Acquire Crinetics Pharmaceuticals (CRNX) in $85 Per Share Cash Deal
- Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy?
- Vertex Pharmaceuticals Bets $10 Billion on Crinetics to Build Endocrinology Powerhouse
- Why This Pharmaceutical Stock Jumped Close to 100% This Week
- Crinetics Pharmaceuticals (CRNX) is One of the Best AI Driven Biotech Stocks, Here is Why
我的指标 您的个人关注列表 — 来自完整基本面的选定行
📊
选择对您重要的指标 — 点击上方完整基本面中任意行的 ➕。
您的选择已保存，并会跟随您浏览所有股票。
机构持有人 (13F) 287 家申报者 · $3.2B 总计 · 截至 2026年6月30日
在其季度SEC表格13F中报告持有此股票的机构。仅限多头头寸；单个申报人可能因单独的期权腿而出现两次。 大的抵消性看跌/看涨腿通常反映做市或对冲库存，而非方向性判断。
机构活动 — Q2 2026 与上一季度对比
| 新仓位 | 已退出持仓 | 增加 | 减少 | 净股数变动 |
|---|---|---|---|---|
| 63 (+11 与上一季度对比) | 30 (-13 与上一季度对比) | 95 (-17 与上一季度对比) | 63 (+3 与上一季度对比) | +11.4M |
与Q1 2026对比。 SEC 13F表格的提交截止日期是季度末后45天，外加少量延迟提交的缓冲期——在此窗口期内的季度将被跳过，优先显示最近一个已完整报告的季度对。
| 机构 | 价值 | 股份 | % 已追踪的13F | 类型 |
|---|---|---|---|---|
| FMR LLC | $486250673 | 12994406 | 15.13% | 股份 |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | $336372047 | 8989098 | 10.46% | 股份 |
| Driehaus Capital Management LLC | $241866078 | 6463551 | 7.52% | 股份 |
| WELLINGTON MANAGEMENT GROUP LLP | $237002526 | 6333579 | 7.37% | 股份 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $180836416 | 4832614 | 5.63% | 股份 |
| VANGUARD CAPITAL MANAGEMENT LLC | $177567704 | 4745262 | 5.52% | 股份 |
| STATE STREET CORP | $100635477 | 2689350 | 3.13% | 股份 |
| Bellevue Group AG | $98040400 | 2620000 | 3.05% | 股份 |
| BAKER BROS. ADVISORS LP | $87991820 | 2351465 | 2.74% | 股份 |
| GEODE CAPITAL MANAGEMENT, LLC | $87542675 | 2338905 | 2.72% | 股份 |
| Polar Capital Holdings Plc | $85108460 | 2274411 | 2.65% | 股份 |
| Pictet Asset Management Holding SA | $77572984 | 2075375 | 2.41% | 股份 |
| Siren, L.L.C. | $53165887 | 1420788 | 1.65% | 股份 |
| First Light Asset Management, LLC | $50923606 | 1360866 | 1.58% | 股份 |
| NOVO HOLDINGS A/S | $49394400 | 1320000 | 1.54% | 股份 |
| AMERICAN CENTURY COMPANIES INC | $47245129 | 1262562 | 1.47% | 股份 |
| ADAR1 Capital Management, LLC | $45730234 | 1222080 | 1.42% | 股份 |
| DIMENSIONAL FUND ADVISORS LP | $44555208 | 1190679 | 1.39% | 股份 |
| MONTANOVA CAPITAL, LLC | $44390560 | 1186279 | 1.38% | 股份 |
| ORBIMED ADVISORS LLC | $37382580 | 999000 | 1.16% | 股份 |
| Hood River Capital Management LLC | $36259830 | 968996 | 1.13% | 股份 |
| GOLDMAN SACHS GROUP INC | $34657132 | 926166 | 1.08% | 股份 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $32841401 | 877643 | 1.02% | 股份 |
| Aberdeen Group plc | $30699181 | 820395 | 0.95% | 股份 |
| Candriam S.C.A. | $30618690 | 819032 | 0.95% | 股份 |
| VANGUARD FIDUCIARY TRUST CO | $28230995 | 754436 | 0.88% | 股份 |
| Fisher Asset Management, LLC | $27748912 | 741553 | 0.86% | 股份 |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $17709036 | 479400 | 0.55% | 股份 |
| AMERIPRISE FINANCIAL INC | $17451149 | 466356 | 0.54% | 股份 |
| Impax Asset Management Group plc | $16277700 | 435000 | 0.51% | 股份 |
| Prosight Management, LP | $14020002 | 374666 | 0.44% | 股份 |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $13991714 | 373910 | 0.44% | 股份 |
| KENNEDY CAPITAL MANAGEMENT LLC | $13685018 | 365714 | 0.43% | 股份 |
| BRAUN STACEY ASSOCIATES INC | $13027511 | 348143 | 0.41% | 股份 |
| Fiera Capital Corp | $12395263 | 331247 | 0.39% | 股份 |
| BANK OF AMERICA CORP /DE/ | $11271877 | 301226 | 0.35% | 股份 |
| Defilade Capital Management, L.P. | $8959845 | 239440 | 0.28% | 股份 |
| SEB Asset Management AB | $8003786 | 213891 | 0.25% | 股份 |
| Foresite Capital Management VI LLC | $7933414 | 212010 | 0.25% | 股份 |
| RICE HALL JAMES & ASSOCIATES, LLC | $7346220 | 196318 | 0.23% | 股份 |
| TD Asset Management Inc | $7152534 | 191142 | 0.22% | 股份 |
| Swiss National Bank | $6877796 | 183800 | 0.21% | 股份 |
| SEGALL BRYANT & HAMILL, LLC | $6855307 | 183199 | 0.21% | 股份 |
| BlackRock, Inc. | $6781290 | 181221 | 0.21% | 股份 |
| JENNISON ASSOCIATES LLC | $6056839 | 161861 | 0.19% | 股份 |
| New Leaf Venture Partners, L.L.C. | $5872650 | 141000 | 0.18% | 股份 |
| SILVERCREST ASSET MANAGEMENT GROUP LLC | $5865136 | 156738 | 0.18% | 股份 |
| Foresite Capital Management IV, LLC | $5613000 | 150000 | 0.17% | 股份 |
| Bank of New York Mellon Corp | $5581754 | 149165 | 0.17% | 股份 |
| NEW YORK STATE COMMON RETIREMENT FUND | $5508898 | 147218 | 0.17% | 股份 |
| ENVESTNET ASSET MANAGEMENT INC | $5471384 | 146216 | 0.17% | 股份 |
| Moody Aldrich Partners LLC | $5466201 | 146077 | 0.17% | 股份 |
| Ishara Investments LP | $5369770 | 143500 | 0.17% | 股份 |
| CITADEL ADVISORS LLC | $5176271 | 138329 | 0.16% | 股份 |
| RHUMBLINE ADVISERS | $4861141 | 129908 | 0.15% | 股份 |
| ALLIANCEBERNSTEIN L.P. | $4782618 | 131680 | 0.15% | 股份 |
| GordonMD Global Investments LP | $4751779 | 126985 | 0.15% | 股份 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $4712974 | 125948 | 0.15% | 股份 |
| JANUS HENDERSON GROUP PLC | $4700428 | 129392 | 0.15% | 股份 |
| Cormorant Asset Management, LP | $4677500 | 125000 | 0.15% | 股份 |
| SECTOR GAMMA AS | $4289380 | 114628 | 0.13% | 股份 |
| XTX Topco Ltd | $4164547 | 111292 | 0.13% | 股份 |
| ALPS ADVISORS INC | $3981825 | 106409 | 0.12% | 股份 |
| FEDERATED HERMES, INC. | $3957390 | 105756 | 0.12% | 股份 |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $3834048 | 105563 | 0.12% | 股份 |
| Nuveen Asset Management, LLC | $3760151 | 73541 | 0.12% | 股份 |
| Burkehill Global Management, LP | $3742000 | 100000 | 0.12% | 股份 |
| Nuveen, LLC | $3619262 | 96720 | 0.11% | 股份 |
| VICTORY CAPITAL MANAGEMENT INC | $3484251 | 93112 | 0.11% | 股份 |
| MORGAN STANLEY | $3320829 | 88744 | 0.10% | 股份 |
| TWO SIGMA INVESTMENTS, LP | $3266729 | 87299 | 0.10% | 股份 |
| VANGUARD ASSET MANAGEMENT, Ltd | $3254754 | 86979 | 0.10% | 股份 |
| AWM Investment Company, Inc. | $3180700 | 85000 | 0.10% | 股份 |
| Odyssean, LLC | $3160344 | 84456 | 0.10% | 股份 |
| Affinity Asset Advisors, LLC | $2806500 | 75000 | 0.09% | 股份 |
| ALGERT GLOBAL LLC | $2714147 | 72532 | 0.08% | 股份 |
| ExodusPoint Capital Management, LP | $2652404 | 70882 | 0.08% | 股份 |
| Ensign Peak Advisors, Inc | $2507290 | 67004 | 0.08% | 股份 |
| BARCLAYS PLC | $2466127 | 65904 | 0.08% | 股份 |
| FIRST TRUST ADVISORS LP | $2370631 | 63352 | 0.07% | 股份 |
| Man Group plc | $2284229 | 61043 | 0.07% | 股份 |
| MetLife Investment Management, LLC | $2258709 | 60361 | 0.07% | 股份 |
| CITIGROUP INC | $2255229 | 60268 | 0.07% | 股份 |
| Longaeva Partners L.P. | $2184879 | 58388 | 0.07% | 股份 |
| Swedbank AB | $2155392 | 57600 | 0.07% | 股份 |
| STATE OF WISCONSIN INVESTMENT BOARD | $2068016 | 55265 | 0.06% | 股份 |
| Jump Financial, LLC | $1923388 | 51400 | 0.06% | 股份 |
| Lighthouse Investment Partners, LLC | $1871000 | 50000 | 0.06% | 股份 |
| Vestmark Advisory Solutions, Inc. | $1823252 | 48724 | 0.06% | 股份 |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $1787254 | 47762 | 0.06% | 股份 |
| VANGUARD GROUP INC | $1774626 | 38123 | 0.06% | 股份 |
| Point72 Asset Management, L.P. | $1735577 | 46381 | 0.05% | 股份 |
| BNP PARIBAS FINANCIAL MARKETS | $1696398 | 45334 | 0.05% | 股份 |
| RAYMOND JAMES FINANCIAL INC | $1606254 | 42925 | 0.05% | 股份 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1549188 | 41400 | 0.05% | 买入期权 |
| Invesco Ltd. | $1545446 | 41300 | 0.05% | 股份 |
| Vanguard Global Advisers, LLC | $1485986 | 39711 | 0.05% | 股份 |
| HighMark Wealth Management LLC | $1444224 | 38595 | 0.04% | 股份 |
| OAK RIDGE INVESTMENTS LLC | $1405046 | 37548 | 0.04% | 股份 |
| Orion Porfolio Solutions, LLC | $1404234 | 37526 | 0.04% | 股份 |
公司内部人士 20 位内幕人士 · 9 位高管 · 10 位董事
| 内部人士 | 角色 | 上次活动 | 持股数量 | 买入 12个月 | 卖出 12个月 | 净额 12个月 |
|---|---|---|---|---|---|---|
| Tobin Schilke | Chief Financial Officer | 2025年3月10日 A | 52000 | 0 | 0 | $0 |
| Marc Wilson | CFO | 2024年9月26日 M | 111092 | 0 | 0 | $0 |
| Jeff E. Knight | Chief Operating Officer | 2025年3月19日 S | 87491 | 0 | 0 | $0 |
| Stephen F. Betz | Chief Scientific Officer | 2025年6月12日 M | 99713 | 0 | 0 | $0 |
| Dana Pizzuti | Chief Med and Dev Officer | 2025年3月19日 S | 72233 | 0 | 0 | $0 |
| Isabel Kalofonos | Chief Commercial Officer | 2025年1月10日 A | — | 0 | 0 | $0 |
| James Hassard | Chief Commercial Officer | 2024年7月5日 M | 29259 | 0 | 0 | $0 |
| Alan Seth Krasner | Chief Medical Officer | 2023年10月17日 M | 43210 | 0 | 0 | $0 |
| Ajay Madan | Chief Development Officer | 2022年2月28日 A | 176995 | 0 | 0 | $0 |
| Coelho Rogerio Vivaldi | 董事 | 2026年7月2日 S | 19225 | 0 | 1 | $-120000 |
| Caren Deardorf | 董事 | 2026年6月18日 A | 22225 | 0 | 0 | $0 |
| Weston Nichols | 董事 | 2026年6月18日 A | 22225 | 0 | 0 | $0 |
| Stephanie Okey | 董事 | 2026年6月18日 A | 12325 | 0 | 2 | $-246143 |
| Matthew K Fust | 董事 | 2026年6月18日 A | 28761 | 0 | 0 | $0 |
| Camille L Bedrosian | 董事 | 2026年6月18日 A | 22225 | 0 | 0 | $0 |
| Wendell Wierenga | 董事 | 2026年6月18日 A | 122071 | 0 | 0 | $0 |
| Wendall Wierenga | 董事 | 2025年6月11日 A | 116146 | 0 | 0 | $0 |
| Stephen W Kaldor | 董事 | 2020年6月19日 A | — | 0 | 0 | $0 |
| Jack Nielsen | 董事 | 2019年6月21日 A | — | 0 | 0 | $0 |
| Richard Scott Struthers | — | 2026年8月7日 M | 424706 | 0 | 0 | $0 |
来自SEC表格3/4/5申报的内部人士；净额=仅公开市场买卖
激进投资者及 5%+ 股东 1 持仓
提交了 SEC Schedule 13D 的投资者 — 持有超过 5% 的受益所有权，意图影响发行人（激进股东持股、董事会活动、并购）。每一行显示该申报人持仓的最新已知状态。
| 申报人 | 已申报 | 持股 | 状态 | 目的 | 申报 |
|---|---|---|---|---|---|
| Perceptive Advisors LLC, Joseph Edelman, Perceptive Life Sciences Master Fund, Ltd. ×6 申报 | 2024年3月1日 | — | 初始申报 | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF持仓 由 55 只交易所交易基金持有
权重仅反映直接股权持仓（N-PORT）；杠杆基金或基于衍生品的基金可能持有未显示的额外掉期敞口。
| 基金 | 权重 | 单位 | 截至 | 来源 |
|---|---|---|---|---|
| SBIO · ALPS ETF Trust | 2.37% | 107892 NS | 2026年5月31日 | N-PORT |
| FMED · Fidelity Covington Trust | 1.65% | 19000 NS | 2026年5月31日 | N-PORT |
| PILL · Direxion Shares ETF Trust | 1.40% | 4666 NS | 2026年4月30日 | N-PORT |
| BBP · ETFis Series Trust I | 1.23% | 18743 NS | 2026年4月30日 | N-PORT |
| MMSC · First Trust Exchange-Traded Fund ... | 0.75% | 11043 NS | 2026年5月31日 | N-PORT |
| NUSC · Nushares ETF Trust | 0.28% | 93045 NS | 2026年4月30日 | N-PORT |
| BBSC · J.P. Morgan Exchange-Traded Fund ... | 0.20% | 38553 NS | 2026年4月30日 | N-PORT |
| BIB · ProShares Trust | 0.19% | 3872 NS | 2026年5月31日 | N-PORT |
| BKSE · BNY Mellon ETF Trust | 0.15% | 3142 NS | 2026年4月30日 | N-PORT |
| FNY · First Trust Exchange-Traded Alpha... | 0.14% | 18879 NS | 2026年4月30日 | N-PORT |
| RSSL · Global X Funds | 0.12% | 42391 NS | 2026年4月30日 | N-PORT |
| FFSM · FIDELITY COVINGTON TRUST | 0.10% | 31759 NS | 2026年4月30日 | N-PORT |
| ITWO · ProShares Trust | 0.09% | 4601 NS | 2026年5月31日 | N-PORT |
| SCHA · SCHWAB STRATEGIC TRUST | 0.08% | 492431 NS | 2026年5月31日 | N-PORT |
| FNX · First Trust Exchange-Traded Alpha... | 0.07% | 24991 NS | 2026年4月30日 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0.06% | 41183 NS | 2026年4月30日 | N-PORT |
| DFAS · Dimensional ETF Trust | 0.05% | 196549 NS | 2026年4月30日 | N-PORT |
| UWM · ProShares Trust | 0.05% | 3599 NS | 2026年5月31日 | N-PORT |
| FAD · First Trust Exchange-Traded Alpha... | 0.04% | 5196 NS | 2026年4月30日 | N-PORT |
| AVIE · AMERICAN CENTURY ETF TRUST | 0.04% | 112 NS | 2026年5月31日 | N-PORT |
| URTY · ProShares Trust | 0.04% | 3643 NS | 2026年5月31日 | N-PORT |
| GSSC · Goldman Sachs ETF Trust | 0.02% | 5689 NS | 2026年5月31日 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0.02% | 3773 NS | 2026年5月31日 | N-PORT |
| HDG · ProShares Trust | 0.02% | 91 NS | 2026年5月31日 | N-PORT |
| DFAC · Dimensional ETF Trust | 0.01% | 125853 NS | 2026年4月30日 | N-PORT |
| ONEQ · Fidelity Commonwealth Trust | 0.01% | 28694 NS | 2026年5月31日 | N-PORT |
| DCOR · Dimensional ETF Trust | 0.01% | 5863 NS | 2026年4月30日 | N-PORT |
| TILT · FlexShares Trust | 0.01% | 3388 NS | 2026年4月30日 | N-PORT |
| DFUS · Dimensional ETF Trust | 0.01% | 31413 NS | 2026年4月30日 | N-PORT |
| DFAU · Dimensional ETF Trust | 0.01% | 15024 NS | 2026年4月30日 | N-PORT |
| SCHB · SCHWAB STRATEGIC TRUST | 0.01% | 60503 NS | 2026年5月31日 | N-PORT |
| DXUV · Dimensional ETF Trust | 0.00% | 468 NS | 2026年4月30日 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | — | — | 2026年7月15日 | 每日 |
| VB · VANGUARD INDEX FUNDS | — | — | 2026年7月15日 | 每日 |
| VBK · VANGUARD INDEX FUNDS | — | — | 2026年7月15日 | 每日 |
| VTI · VANGUARD INDEX FUNDS | — | — | 2026年7月15日 | 每日 |
| VT · VANGUARD INTERNATIONAL EQUITY IND... | — | — | 2026年7月15日 | 每日 |
| VTWO · VANGUARD SCOTTSDALE FUNDS | — | — | 2026年7月15日 | 每日 |
| VTWG · VANGUARD SCOTTSDALE FUNDS | — | — | 2026年7月15日 | 每日 |
| VTHR · VANGUARD SCOTTSDALE FUNDS | — | — | 2026年7月15日 | 每日 |
| ITOT · iShares Trust | — | — | 2026年8月5日 | 每日 |
| IWV · iShares Trust | — | — | 2026年8月18日 | 每日 |
| IWO · iShares Trust | — | — | 2026年8月18日 | 每日 |
| IWM · iShares Trust | — | — | 2026年8月18日 | 每日 |
| IBB · iShares Trust | — | — | 2026年8月18日 | 每日 |
| IHE · iShares Trust | — | — | 2026年8月18日 | 每日 |
| PRFZ · Invesco Exchange-Traded Fund Trust | — | — | 2026年8月4日 | 每日 |
| OMFS · Invesco Exchange-Traded Self-Inde... | — | — | 2026年7月13日 | 每日 |
| VHT · VANGUARD WORLD FUND | — | — | 2026年7月20日 | 每日 |
| ESGV · VANGUARD WORLD FUND | — | — | 2026年7月30日 | 每日 |